mNGS: The Genetic Test That Finds Almost Every Infection

A Broader Approach to Infection Diagnosis

Diagnosing an infection often starts with a focused question: Which pathogen is most likely? A clinician may order a polymerase chain reaction (PCR) test for one virus, a bacterial culture, an antigen test or a panel covering several organisms.

This approach works when the suspected cause is correct. It is less effective when symptoms are severe but nonspecific, the organism is unusual, antibiotics have already been started or more than one pathogen is present. A negative result may reflect the wrong target rather than the absence of infection.

Metagenomic next-generation sequencing, or mNGS, offers a broader strategy. Instead of looking for one suspected organism, it examines genetic material in a patient sample and compares the sequences with databases containing bacteria, viruses, fungi and parasites. The approach has attracted attention as a possible broad-spectrum infection test, including reports about a genetic technique designed to detect almost every infection Source 1.

“Almost every infection” describes the breadth of the search, not a guarantee. mNGS cannot detect genetic material that is absent, hidden by a poor sample or missing from a reference database. Its results still require clinical interpretation.

What Is mNGS?

Metagenomic Sequencing Searches Broadly

mNGS analyzes all, or nearly all, genetic material recovered from a biological sample rather than testing only for a preselected pathogen.

A targeted test asks whether the genetic signature of influenza, tuberculosis or a particular bacterium is present. A broad genomic test asks a wider question: What microbial genetic material is present in this sample?

Depending on the method and sample, mNGS may identify evidence from:

• Bacteria
• Viruses
• Fungi
• Parasites
• Multiple organisms at the same time

The technique can analyze DNA, RNA or both. Some pathogens contain DNA, while others are RNA-based. Laboratories select extraction and sequencing methods according to the suspected infection, sample type and sequencing platform.

The broad idea matches reporting about a genetic technique intended to detect almost every infection. However, the supplied BBC summary does not provide detailed methodological findings. Its headline should not be interpreted as proof that one test detects every pathogen in every patient Source 1.

How the Test Identifies Pathogens

A typical mNGS workflow includes five stages:

1. Sample collection: A clinician collects blood, respiratory fluid, cerebrospinal fluid, tissue, urine or another relevant specimen.
2. Genetic extraction: The laboratory extracts DNA, RNA or both.
3. Sequencing: A sequencing platform reads millions of small genetic fragments.
4. Database comparison: Software compares the fragments with reference genomes from known organisms.
5. Clinical reporting: Laboratory specialists assess which signals may represent pathogens and report the findings.

Unlike culture, sequencing does not always require an organism to grow. This matters because some pathogens grow slowly, require specialized conditions or become difficult to recover after antimicrobial treatment.

Detection is not the same as proof of active disease. Sequencing can identify genetic material from a living organism, a dead organism, a colonizer or a contaminant. Laboratories must consider the amount of detected material, the sample site, background microbial DNA and the patient’s symptoms.

Why Conventional Tests Can Miss the Cause

Targeted Tests Depend on the Initial Suspicion

PCR and antigen tests are often rapid and accurate for their intended targets. Their limitation is scope. A test designed to detect one virus usually cannot identify an unrelated bacterium. A respiratory panel may cover common organisms but exclude rare fungi or newly recognized pathogens.

Many infections produce overlapping symptoms, including fever, headache, breathing difficulty, confusion, diarrhea and inflammation. These symptoms can also result from noninfectious conditions.

When the initial suspicion is wrong, clinicians may need to order additional tests. This can delay diagnosis, increase costs and expose patients to repeated procedures. A broad infection test may reduce the number of separate tests required in selected complex cases.

Targeted tests remain valuable. When a clinician strongly suspects one pathogen, focused PCR can be faster, less expensive and easier to interpret than broad sequencing. mNGS is most useful when the diagnostic question is wide or routine testing has failed.

Cultures Can Be Slow or Unsuccessful

Culture attempts to grow an organism under suitable laboratory conditions. When successful, it provides an important advantage: a live isolate can often be tested against antimicrobial drugs.

Culture has limitations. The organism may be present in very small numbers, require special nutrients or fail to survive transport. Antibiotics taken before sampling can reduce the chance of growth. A poorly collected specimen may not contain material from the infected site.

Some infections are difficult to sample because they occur in deep tissue, the brain, the bloodstream or another high-risk location. A negative culture may mean that the organism was absent, too scarce, nonviable or not recoverable under the laboratory conditions.

Sequencing may detect genetic fragments when culture fails, but it does not automatically provide a living organism for drug-susceptibility testing. The two methods answer related but different questions.

What mNGS Could Change

Investigating Complex Infections Faster

A novel genomic test reported by CIDRAP on November 20, 2024, showed promise for streamlining diagnosis across multiple infectious diseases Source 9.

One broad test could reduce the need for many individual pathogen tests. Earlier identification could help clinicians select targeted treatment, stop unnecessary antimicrobials or involve specialists sooner.

This potential benefit is especially important when broad-spectrum antibiotics are started before the cause is known. Such treatment may be necessary in critically ill patients, but prolonged use can cause side effects and contribute to antimicrobial resistance. A reliable diagnosis could support narrower therapy.

“Shows promise” does not mean that mNGS is ready to replace established diagnostics. Its usefulness depends on performance, turnaround time, cost and whether results change treatment or improve patient outcomes.

Detecting Unexpected or Rare Pathogens

Broad sequencing may help when an illness does not fit common diagnostic patterns. Potential applications include:

• Severe unexplained illness
• Central nervous system infections
• Illness in immunocompromised patients
• Persistent symptoms after negative routine tests
• Suspected infections caused by unusual organisms
• Outbreak investigations

Rare-pathogen detection depends on several conditions. The organism must be present in the sample, its genetic material must be detectable and the reference database must contain a sufficiently similar sequence. A weak or incomplete database match may require additional testing before treatment begins.

Identifying Coinfections

A sample may contain genetic evidence of multiple organisms. This could reveal coinfections that a single-target PCR test would miss.

However, finding several sequences does not prove that every detected organism is causing disease. Respiratory and skin-adjacent samples naturally contain microbial communities. A result may reflect colonization, contamination or harmless background material.

Clinicians must compare the result with symptoms, imaging, inflammatory markers, culture, exposure history and treatment response. The strongest result is not necessarily the longest list of detected organisms. It is the finding that best fits the patient’s condition and the sample site.

How Accurate Is “Almost Every Infection”?

Broad Coverage Does Not Mean Perfect Detection

No infection test detects every disease in every sample. mNGS can fail when:

• The sample comes from the wrong body site.
• The sample contains too little material.
• The pathogen level is below the detection threshold.
• Genetic material has degraded.
• Human DNA overwhelms the microbial signal.
• The pathogen is absent from the reference database.
• Laboratory contamination obscures the result.
• The illness is noninfectious.

A negative mNGS result lowers the likelihood of detecting infections covered by the analysis. It does not rule out every possible infection or noninfectious explanation.

Genetic Material Is Not the Same as Active Infection

Sequencing may detect DNA or RNA from living organisms, dead organisms, colonizing organisms or contaminants. Genetic material may remain after treatment has killed a pathogen. A respiratory specimen may contain an organism that colonizes the airway without causing pneumonia. A low-level signal may come from laboratory reagents or sample handling rather than the patient.

Results should be considered alongside:

• Symptoms and physical examination
• Imaging
• Blood tests
• Culture
• Targeted PCR
• Treatment history
• Immune status
• The location and quality of the sample

The appropriate response to sequence detection is not automatic treatment. It is a clinical assessment of whether the finding explains the illness.

Sample Type Determines Performance

mNGS performance varies by sample type. Cerebrospinal fluid may contain relatively little microbial material, but a positive result can be clinically important. Respiratory specimens may contain more microbial DNA but also more colonizing organisms. Blood can be difficult because pathogen levels may be extremely low while human DNA is abundant.

Tissue may provide a strong link to disease when collected from the infected site. Urine and other samples have their own background microbial communities and contamination risks.

Accuracy claims should specify the sample type, pathogen group, laboratory method and clinical setting. A single sensitivity figure cannot describe every use of mNGS.

How mNGS Compares With Other Infection Tests

Culture

Strengths:

• Provides live organisms when successful
• Can support antimicrobial susceptibility testing
• Remains essential for many bacterial infections

Limitations:

• May take time
• Can fail after antibiotic exposure
• Does not grow every organism
• Requires suitable samples and laboratory conditions

PCR and Other Targeted Molecular Tests

Strengths:

• Often rapid
• Sensitive for selected pathogens
• Useful when clinical suspicion is strong

Limitations:

• Usually cannot identify organisms outside the test panel
• Multiple tests may be needed when the diagnosis is uncertain
• A negative result may reflect an incorrect target

Antigen and Antibody Tests

Strengths:

• Can be fast and practical
• Useful for selected infections
• May support diagnosis when molecular testing is unavailable

Limitations:

• Sensitivity varies
• Antibody responses may take time to develop
• Antigen tests cover specific organisms or groups

Metagenomic Sequencing

Strengths:

• Searches broadly across pathogen groups
• May detect unusual or mixed infections
• Does not always require organism growth
• Can expand the diagnostic search after routine tests fail

Limitations:

• Can be expensive
• Requires specialized laboratory and bioinformatics capacity
• May detect contamination or colonization
• Results require expert interpretation
• Access and turnaround time vary

These methods are complementary. A clinician may use targeted testing for common causes, culture for organism recovery and susceptibility testing, and mNGS when the cause remains unclear.

Where mNGS Could Be Most Useful

Unexplained Severe Illness

Broad testing may support diagnosis when a patient is critically ill and routine investigations are negative. It can be valuable when delayed treatment carries substantial risk.

Urgent treatment should not wait for sequencing results when clinical evidence supports immediate therapy. mNGS is an additional diagnostic tool, not a reason to delay emergency care.

Brain and Spinal Infections

Cerebrospinal fluid can be important in suspected meningitis or encephalitis. When standard testing does not identify the cause, mNGS may broaden the search to bacteria, viruses, fungi and parasites.

It does not replace cell counts, chemistry, culture, targeted PCR, imaging or other cerebrospinal fluid investigations. A negative result also does not eliminate the need for continued evaluation.

Immunocompromised Patients

People with weakened immune systems may develop unusual, simultaneous or difficult-to-detect infections. Their symptoms may be atypical, and multiple organisms may be present.

mNGS can expand the initial search, but interpretation may be complicated by low pathogen levels, prior treatment and complex microbial backgrounds. Results require coordination between laboratory specialists and clinicians.

Public Health and Outbreak Response

Broad pathogen detection may help investigate unexplained clusters and identify unexpected organisms. This use differs from individual diagnosis because public health teams also examine patterns across people, locations and time.

A single mNGS result can suggest an infectious cause, but outbreak confirmation usually requires additional epidemiological, laboratory and sometimes culture-based evidence.

Barriers to Broad Clinical Adoption

Cost and Laboratory Capacity

Sequencing platforms, sample preparation, quality control and bioinformatics require investment. Large medical centers may have greater access than smaller facilities. Sending samples to an external laboratory can add transport time and cost.

Cost-effectiveness depends on clinical impact. A test may justify its cost if it reduces hospital stays, repeated procedures, unnecessary treatment or delayed diagnosis. Those benefits require measurement in real-world studies.

Reference Databases and Interpretation

Results depend partly on reference databases. Missing or poorly represented organisms can produce uncertain matches. Closely related organisms may also be difficult to distinguish.

Laboratories need standardized reporting thresholds. They must separate clinically meaningful signals from background genetic material and contamination. Clear reports should explain confidence, organism abundance and limitations.

Clinical Validation

Promising early findings require confirmation in larger and more diverse patient populations. Studies should assess:

• Sensitivity and specificity
• False-positive and false-negative rates
• Turnaround time
• Performance by sample type
• Effects on treatment decisions
• Effects on hospital stays and patient outcomes
• Comparisons with established diagnostic pathways

A technically impressive test has limited value if clinicians cannot interpret it or if it rarely changes care.

Privacy and Data Governance

Genomic testing may generate human genetic information alongside pathogen data. Clinical programs need clear policies for data storage, access controls, patient consent, secondary research use and de-identification.

Responsible implementation should limit access to necessary personnel and explain how data are handled. Governance must keep pace with technical capability.

What Patients Should Know

It Is Not a Universal Health Screen

mNGS is generally considered for specific clinical situations, not routine screening of healthy people. Testing decisions depend on symptoms, illness severity, sample type, availability and the treating team’s judgment.

A Positive Result May Need Confirmation

Clinicians may use culture, targeted PCR, imaging, repeat sampling or another method to confirm that a detected organism is clinically significant. Treatment should reflect the complete clinical picture.

A Negative Result Does Not End the Investigation

Further evaluation may be necessary when symptoms remain severe or unexplained. Noninfectious conditions, sampling problems and infections outside the test’s effective range can all produce a negative result.

The Future of Infection Diagnosis

The most likely role for mNGS is as part of a layered diagnostic strategy:

1. Use rapid targeted tests for common infections.
2. Use culture when live organisms and drug-susceptibility data are needed.
3. Use broad sequencing for severe, unexplained or atypical cases.

Future improvements may include larger pathogen databases, faster sequencing, lower costs, stronger contamination controls and better interpretation software. Standardized reporting could make results easier to compare across laboratories.

The technique’s value depends on reliable sampling and expert interpretation. It may widen the diagnostic net, but it cannot overcome the absence of pathogen material or replace clinical judgment.

The unrelated supplied reports do not provide evidence for infection-test performance. The cell-lineage study concerns developmental biology, while the sports, politics and entertainment entries are unrelated. The pneumonic-plague report concerns outbreak risk rather than genomic diagnostic accuracy Source 7.

Conclusion: A Wider Diagnostic Net, Not a Perfect Test

mNGS can search one patient sample for genetic evidence from many bacteria, viruses, fungi and parasites. Its broad coverage may help identify unexpected pathogens, mixed infections and causes missed by targeted tests.

The technique also has important limits. It cannot detect material that is absent from the sample. It may identify dead organisms, colonization or contamination. It does not always provide a live pathogen for drug-susceptibility testing, and it does not replace clinical judgment or every conventional diagnostic method.

The genetic technique that finds almost every infection is best understood as a wider diagnostic net, not a perfect test. With stronger validation, faster workflows, better databases and responsible implementation, mNGS could change how difficult infections are investigated.

Frequently Asked Questions

What is the genetic technique that can detect almost every infection?

The technique is generally called metagenomic next-generation sequencing, or mNGS. It searches a patient sample for genetic material from many possible pathogens instead of targeting one organism at a time. “Almost every” refers to broad coverage, not guaranteed detection.

Can mNGS detect bacteria, viruses, fungi and parasites?

mNGS can potentially detect genetic material from all four groups. Success depends on the sample, pathogen abundance, database coverage, extraction method and sequencing platform. Detection does not automatically prove active infection.

Is metagenomic sequencing better than culture or PCR?

It is not universally better. mNGS offers broader coverage. Culture can provide live organisms for susceptibility testing, while PCR can be faster and highly sensitive for known targets. Clinicians may use these methods together.

Can the test find an infection after antibiotics have started?

Sequencing may detect genetic material after antibiotics reduce the chance of successful culture. However, treatment can also lower the amount of detectable material. Results still depend on sample timing, sample quality and pathogen abundance.

What does a negative mNGS result mean?

A negative result lowers the likelihood of detecting infections covered by the analysis, but it does not rule out every cause. Possible explanations include poor sample quality, low pathogen levels, sampling from the wrong site, incomplete database coverage or a noninfectious illness.

When might a doctor order broad genomic infection testing?

A clinician might consider it for severe unexplained illness, suspected central nervous system infection, immunocompromised patients, persistent symptoms after negative routine tests or possible mixed infections. Availability, cost and local protocols also influence its use.